🇺🇸 FDA
Pipeline program

611 150mg

SSGJ-611-AD-I-C

Phase 2 small_molecule completed

Quick answer

611 150mg for Dermatitis, Atopic is a Phase 2 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Dermatitis, Atopic
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials